List of Excipients in Branded Drug PREVALITE

« Back to Dashboard

Generic Drugs Containing PREVALITE

Company	Ingredient	NDC	Excipient
Upsher-Smith Laboratories LLC	cholestyramine	0245-0036	ASPARTAME
Upsher-Smith Laboratories LLC	cholestyramine	0245-0036	FD&C YELLOW NO. 6
Upsher-Smith Laboratories LLC	cholestyramine	0245-0036	MALIC ACID
Upsher-Smith Laboratories LLC	cholestyramine	0245-0036	POLYSORBATE 80
Upsher-Smith Laboratories LLC	cholestyramine	0245-0036	PROPYLENE GLYCOL ALGINATE

What are the Most Frequently-Used Excipients in PREVALITE?

# Of NDCs	Excipient
1	ASPARTAME
1	FD&C YELLOW NO. 6
1	MALIC ACID
1	POLYSORBATE 80
1	PROPYLENE GLYCOL ALGINATE

Prevalite Excipient Strategy and Commercial Opportunities: Cholestyramine Formulation, Patents, and Generic Risk

Last updated: October 16, 2026

Prevalite is an oral powder containing 4 grams of cholestyramine for suspension. Its commercial opportunity is driven less by active-ingredient exclusivity and more by formulation execution: palatability, dispersibility, adherence, packaging, sugar and phenylalanine positioning, and reliable supply of the ion-exchange resin. The active ingredient is old, generic competition is established, and the FDA public record does not identify a meaningful current Orange Book patent barrier for Prevalite. The strongest opportunities are differentiated reformulations and private-label products rather than conventional patent protection around cholestyramine itself.[1-4]

What is Prevalite and how does its formulation work?

Prevalite is a prescription oral powder containing cholestyramine, a nonabsorbed bile-acid sequestrant. Patients mix the powder with water or another suitable liquid before administration. The drug is used primarily to reduce elevated cholesterol and to manage bile-acid-related conditions, including bile-acid diarrhea in selected clinical settings.[1,2]

Cholestyramine is a strongly basic anion-exchange resin. It binds bile acids in the gastrointestinal tract and prevents their reabsorption. The resin does not dissolve in the conventional sense. Product performance therefore depends on particle size, hydration, wetting, dispersion, suspension behavior, and administration instructions rather than on dissolution alone.

The formulation has four commercial constraints:

1. The resin has an unpleasant taste and gritty mouthfeel.
2. The powder can clump if added improperly to liquid.
3. The product can interfere with absorption of other medicines.
4. Gastrointestinal adverse effects can reduce adherence.

These constraints make excipient selection commercially important even when the underlying active ingredient is mature.

What excipients are used in Prevalite?

Prevalite labeling identifies excipients used to support flavor, powder handling, suspension, and product acceptability. Public labeling has identified components including flavoring materials, citric acid, maltodextrin, propylene glycol alginate, sweetening agents, sodium chloride, and colorants, although the precise composition may vary by presentation and current labeling version.[1,2]

The functional roles are more important than the individual ingredient names:

Formulation function	Relevant excipient category	Commercial purpose
Sweetness	Aspartame, sucrose, or other sweetener system	Masks resin bitterness and improves adherence
Flavor	Orange or other flavor system	Reduces perception of resin taste
Acidification	Citric acid	Supports flavor balance and may improve palatability
Suspension and wetting	Propylene glycol alginate and related polymers	Helps disperse resin in liquid
Powder processing	Maltodextrin and carrier materials	Improves flow, bulk density, and sachet filling
Appearance	Approved colorants	Supports product recognition and flavor association
Electrolyte adjustment	Sodium chloride where used	May affect taste and formulation characteristics

Prevalite’s excipient profile creates several opportunities for line extensions, but any change must preserve the physical behavior of cholestyramine resin. A sweetener substitution that improves labeling may worsen powder flow, hygroscopicity, suspension time, or taste.

Which excipient strategies could improve Prevalite?

Can a sugar-free formulation compete with Prevalite?

Yes. A sugar-free or reduced-sugar formulation is one of the clearest commercial opportunities.

A sugar-free version could target patients with diabetes, metabolic syndrome, long-term treatment needs, or a preference for lower carbohydrate products. Aspartame or a high-intensity sweetener system can reduce sucrose loading, but the formulation must address aftertaste and phenylalanine labeling where applicable.

The product would need to balance:

• Sweetness intensity over the full dosing period
• Metallic or resin-associated aftertaste
• Phenylalanine warnings for aspartame-containing products
• Powder stability under humidity
• Acceptable suspension in water and soft foods
• Compatibility with pediatric and geriatric use

A non-aspartame sugar-free product could provide a stronger differentiation point, especially if it avoids both sucrose and phenylalanine. Steviol glycosides, sucralose, acesulfame potassium, or polyol systems could be evaluated, but each introduces taste, gastrointestinal, or processing considerations.

Can a low-sodium Prevalite formulation create a new market?

Possibly. Sodium-containing excipients may be commercially relevant for patients with cardiovascular, renal, or fluid-retention concerns. A low-sodium product could be positioned for chronic use, although the total sodium contribution from a single dose would need to be established through product-specific labeling.

The commercial value would depend on whether the formulation can maintain taste and powder performance without sodium chloride. Sodium reduction alone is unlikely to support premium pricing unless paired with stronger benefits such as improved palatability, lower sugar, or better packaging.

Can flavor optimization improve adherence?

Flavor remains one of the most valuable formulation targets. Cholestyramine’s resin character is difficult to mask because the product is administered in relatively large quantities and remains in the mouth during mixing and swallowing.

Potential flavor strategies include:

• Citrus profiles with stronger acidity
• Orange-vanilla or citrus-berry systems
• Microencapsulated flavors
• Sequential sweetener systems
• Reduced-color or color-free versions
• Single-serving liquid concentrates or dispersible granules

Flavor systems should be tested in the actual mixed product, not only in dry powder. Resin adsorption can alter flavor release, and the suspension’s viscosity can change how long the taste persists.

Can better dispersibility create defensible differentiation?

Yes. A formulation that wets rapidly, forms fewer clumps, and remains uniformly dispersed for the expected administration window can provide a practical advantage.

Possible approaches include:

• Granulation to improve wetting
• Controlled particle-size distribution
• Porous carrier particles
• Surface modification of the resin
• Improved polymeric suspending systems
• Stick-pack geometry that supports rapid pouring
• Instructions optimized for staged addition of liquid

The formulation must avoid excessive viscosity. A thick suspension may reduce dose transfer from the cup and create residual drug loss.

What patents protect Prevalite and cholestyramine formulations?

Prevalite has limited apparent patent protection around the active ingredient. Cholestyramine has been used clinically for decades, and the core active-ingredient composition is outside the practical life of conventional compound patents.

The relevant intellectual-property opportunities are more likely to involve:

• Specific excipient combinations
• Flavor-masking systems
• Low-sugar or sugar-free compositions
• Improved wetting or dispersion
• Granulated cholestyramine particles
• Unit-dose packaging
• Pediatric administration methods
• Combination products
• New methods of treating bile-acid diarrhea or other conditions

A formulation patent must claim a measurable technical distinction. Broad claims covering “cholestyramine plus a flavor” would face substantial prior-art risk. Stronger claims would require defined excipient ranges, particle attributes, performance thresholds, or comparative data showing improved palatability, suspension uniformity, stability, or adherence.

How strong is the patent estate for Prevalite?

The Prevalite patent estate appears weak relative to modern specialty drugs. The FDA’s public product records identify the product and labeling but do not show a commercially significant remaining period of Orange Book patent exclusivity for the mature cholestyramine formulation.[2,3]

The practical protection may come from:

• Manufacturing know-how
• Resin sourcing
• Flavor system development
• Product-specific stability data
• Packaging validation
• Regulatory filing strategy
• Brand recognition among prescribers and patients

These protections are real but less durable than a valid composition-of-matter patent.

What is the Orange Book status of Prevalite?

Prevalite is an FDA-approved prescription cholestyramine product. The Orange Book and Drugs@FDA records are the principal sources for approval pathway, therapeutic equivalence, patents, exclusivity, and reference-product information.[2,3]

The public record supports the following commercial conclusions:

Issue	Prevalite assessment
Active ingredient	Cholestyramine
Dosage form	Powder for oral suspension
Strength	4 grams per dose
FDA pathway	Legacy approved prescription product
Composition-of-matter patent	Expired or not commercially relevant
Current Orange Book patent barrier	No significant barrier identified in the cited public FDA records
Generic substitution risk	High
Biosimilar risk	Not applicable
Reformulation opportunity	High, subject to regulatory and performance requirements

A new cholestyramine product with the same active ingredient and dosage form may pursue an ANDA if it can meet applicable sameness and bioequivalence requirements. A materially different formulation, new dosage form, or new clinical use could require a 505(b)(2) application, depending on the product’s design and regulatory claims.[4]

When does Prevalite lose exclusivity?

Prevalite’s core market exclusivity has already expired in practical terms. Cholestyramine is an established generic active ingredient, and multiple cholestyramine products have been marketed over time.

The commercial question is therefore not when the first generic can enter. It is whether a new entrant can achieve:

• FDA approval with acceptable product performance
• Reliable resin and excipient supply
• Competitive reimbursement
• Adequate pharmacy substitution
• Differentiated packaging or patient experience
• Consistent manufacturing at commercial scale

A new product may obtain limited regulatory exclusivity for a qualifying reformulation or new clinical investigation, but such exclusivity would not restore broad control over cholestyramine.

Which companies are challenging Prevalite?

Generic competition exists across cholestyramine products, including products sold under generic labeling and legacy brands such as Questran and Questran Light. The competitive field is characterized by mature active-ingredient technology rather than a single high-value Paragraph IV contest.

Public FDA resources do not identify a current, market-defining Paragraph IV litigation campaign directed at Prevalite’s core formulation. Any entrant seeking approval under an ANDA would need to address listed patents and exclusivity in the applicable FDA records, but the commercial risk is primarily formulation equivalence, manufacturing, supply, and reimbursement.

What generic launch risks exist?

The principal launch risks are operational:

1. Resin quality and batch consistency.
2. Powder flow and fill-weight control.
3. Flavor reproducibility.
4. Suspension uniformity.
5. Moisture protection.
6. Raw-material cost.
7. Pharmacy substitution and payer reimbursement.
8. Patient acceptance of a gritty, flavored suspension.

A generic that matches the labeled dose but performs poorly in mixing or taste may lose share quickly, particularly in chronic-use patients.

What formulation patents could support a new product?

The strongest patent candidates would link a defined formulation to a measurable benefit. Examples include:

Improved dispersibility claims

Claims could focus on particle-size distribution, wetting time, sedimentation rate, redispersibility, or residual cup loss.

Taste-masking claims

Claims could define a specific combination of sweetener, flavor, acidulant, polymer, and resin particle treatment that reduces bitterness or aftertaste.

Low-sugar and low-sodium claims

These claims would be more defensible if tied to defined quantitative limits and acceptable organoleptic or performance results.

Pediatric administration claims

A product designed for administration in a small volume of liquid or mixed with a specified soft food could support method or formulation claims, provided the clinical and regulatory strategy is appropriate.

Packaging claims

Unit-dose stick packs, moisture-barrier sachets, and child-resistant multi-dose containers may support design or packaging patents. Packaging claims alone are usually weaker than composition claims but can create incremental barriers.

What regulatory pathway applies to a new Prevalite-like product?

An ANDA is the likely pathway for a product that matches the reference drug in active ingredient, dosage form, strength, route, labeling framework, and relevant quality attributes. Cholestyramine’s nonsolution behavior may make product characterization more complex than for a conventional immediate-release tablet.

A 505(b)(2) pathway may be more suitable for:

• A novel granulated form
• A new delivery format
• A materially different excipient system
• A new indication
• A clinically supported adherence improvement
• A different administration method

FDA review would focus on identity, strength, quality, stability, microbiological control where relevant, container closure, labeling, and evidence that the product performs consistently. The sponsor would also need to manage excipient safety, especially for pediatric use, phenylalanine-containing sweeteners, colorants, and high-intensity flavor systems.[4]

What licensing deals could create commercial value?

Licensing opportunities are more likely to involve technology than the Prevalite brand itself. Potential deal structures include:

Asset	Potential licensee	Commercial rationale
Taste-masking platform	Generic or specialty pharmaceutical company	Improves patient acceptance
Resin granulation technology	Cholestyramine manufacturer	Enables premium or differentiated product
Sugar-free formulation	Branded-generic company	Targets chronic-use and metabolic patients
Pediatric delivery system	Specialty gastrointestinal company	Expands use in children
Private-label product	Retail pharmacy or health system	Supports supply and formulary positioning
Regional rights	Local pharmaceutical distributor	Reduces market-entry cost

A licensing partner would likely value demonstrated human palatability data, scalable manufacturing, freedom-to-operate analysis, and an FDA-compatible development package more than a broad but unvalidated patent application.

What litigation and settlement issues affect Prevalite?

No current, high-value patent litigation or settlement agreement materially affecting Prevalite is identified in the FDA public records cited here. Because the active ingredient and basic dosage form are mature, future disputes would more likely concern:

• A narrow formulation patent
• Trade dress or packaging
• Supplier agreements
• Manufacturing know-how
• Product quality
• ANDA certification
• Labeling differences
• Distribution rights

A settlement involving a new formulation patent would have limited commercial value unless the patent covered a meaningful patient or manufacturing advantage and survived validity and infringement challenges.

How does Prevalite compare with competing bile-acid sequestrants?

Product	Active ingredient	Dosage form	Excipient opportunity	Competitive position
Prevalite	Cholestyramine	Powder for suspension	High, especially taste and dispersion	Established but vulnerable to generic substitution
Questran/Questran Light	Cholestyramine	Powder for suspension	Similar	Legacy brand recognition
Colestipol	Colestipol	Granules or tablets	Moderate	Alternative resin with different administration burden
Colesevelam	Colesevelam	Tablets or suspension	Lower formulation burden for patients	Newer administration profile, often higher cost

Prevalite’s main disadvantage is administration complexity. A tablet-based or more convenient bile-acid sequestrant can command preference despite higher acquisition cost. Its main opportunity is a lower-cost, better-tolerated powder with simpler preparation.

What is the revenue exposure and commercial opportunity?

Prevalite revenue is exposed to generic substitution, payer pressure, and the availability of alternative bile-acid sequestrants. Public FDA sources do not provide a reliable product-level revenue figure, so the commercial opportunity is better assessed through market structure than through a single sales estimate.

The most attractive segments are:

• Private-label generic supply
• Hospital and institutional contracts
• Low-cost chronic therapy
• Bile-acid diarrhea management
• Sugar-free or reduced-sugar products
• Pediatric and geriatric administration
• Unit-dose packaging
• International markets where cholestyramine remains widely used

A premium branded reformulation would need evidence of a clinically relevant benefit. Better taste alone may support adherence and prescriber preference, but payers may still treat the product as interchangeable unless the product obtains a distinct regulatory or formulary position.

What manufacturing and geographic barriers apply?

The major manufacturing barrier is not chemical synthesis. It is control of the resin and finished powder.

Critical manufacturing parameters include:

• Resin identity and exchange capacity
• Particle-size distribution
• Moisture content
• Bulk density
• Flowability
• Blend uniformity
• Flavor uniformity
• Sachet fill accuracy
• Suspension performance
• Container-closure moisture protection

Geographic expansion requires attention to excipient acceptability, colorant rules, sweetener labeling, language requirements, and local registration pathways. A formulation using aspartame, specific colors, or sucrose may face different labeling and market-access requirements by jurisdiction.

Key Takeaways

• Prevalite contains 4 grams of cholestyramine powder for oral suspension.
• The active ingredient is mature and does not provide meaningful new-product exclusivity.
• The principal commercial opportunity is excipient and delivery-system differentiation.
• The strongest targets are taste masking, rapid dispersion, sugar reduction, phenylalanine-free sweetness, low sodium, and unit-dose packaging.
• The public FDA record does not identify a significant current Orange Book patent barrier for the core Prevalite formulation.
• An ANDA may fit a conventional equivalent product; a materially different formulation may require a 505(b)(2) strategy.
• Biosimilar risk is irrelevant because cholestyramine is a small-molecule resin, not a biologic.
• Manufacturing know-how, resin sourcing, flavor reproducibility, and reimbursement are more important barriers than core composition patents.
• A premium product requires evidence that better palatability or administration produces commercially meaningful adherence or utilization benefits.

FAQs

Is Prevalite the same as cholestyramine?

Prevalite is a branded product containing cholestyramine for oral suspension. Generic cholestyramine products may use different excipients, flavors, packaging, and manufacturing processes while containing the same active ingredient and labeled strength.

Does Prevalite contain sugar?

The excipient profile depends on the marketed presentation and current labeling. Some cholestyramine products use sucrose or other sweeteners, while sugar-free versions may use high-intensity sweeteners. The product-specific FDA label controls.

Can cholestyramine be reformulated into a tablet?

A tablet is technically possible but would create substantial dose, compression, swelling, gastrointestinal, and patient-administration challenges. A tablet or caplet could require a different regulatory strategy from a conventional powder equivalent.

Is a better-tasting cholestyramine product patentable?

Potentially, but patent strength depends on the claim structure and data. A specific excipient combination tied to measurable taste, suspension, stability, or adherence improvements is more defensible than a broad claim covering cholestyramine with flavor.

Is there biosimilar competition to Prevalite?

No. Prevalite contains cholestyramine, a nonbiologic small-molecule resin. Competition arises through generic products, alternative bile-acid sequestrants, and reformulated products rather than biosimilars.

References

1. DailyMed. (n.d.). Prevalite- cholestyramine powder, for suspension. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). FDA.